Targeted Therapies

We expect continued focus on targeted therapies in 2021, fueled by significant worldwide market opportunities and promising data in 2020 across a range of targets and diseases. As tumor genomic profiling becomes increasingly prevalent and enhances understanding of the mutations driving certain cancers and rare disease, more companies are focusing on investment in precision medicines as a key pillar of their strategies, suggesting continued M&A.
What we’re watching
Related Themes
Targeted therapies are changing the landscape of cancer treatment and likely will be used in most cancer patients in 5-10 years.
Therapeutic Categories Outlook, October 2020